NVIDIA and Eli Lilly announced a joint investment of approximately $1 billion to establish a co-innovation AI lab

NVIDIA and pharmaceutical giant Eli Lilly announced a joint investment of approximately $1 billion to establish a co-innovation AI lab. The investment, to be deployed over five years, will support the construction of a joint research facility in the San Francisco Bay Area. The lab will leverage NVIDIA's latest Vera Rubin architecture AI chips to advance cutting-edge biomedical research and reinvent drug discovery processes in the age of AI. Kimberly Powell, NVIDIA's Vice President of Healthcare, stated that both companies are committing incremental resources to the new facility. The specific location of the lab is expected to be announced in March 2026, at which point researchers from NVIDIA and Lilly will work side-by-side to generate new datasets for training biotechnology AI models.